Elvitegravir

CHEMBL204656 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
447.9 g/mol
LogP
5.3
Phase
4

This antiviral medication blocks an enzyme that the HIV virus needs to insert its genetic material into human cells. It is always used as part of a combination antiretroviral therapy regimen.

分子量

447.9000 g/mol

LogP

5.30

TPSA

87.10 Ų

リピンスキーの五則

適合

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C

InChI

InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1

Molecular Formula

C23H23ClFNO5

HBD / HBA

2 / 7

回転可能結合数

7

重原子数

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This antiviral medication blocks an enzyme that the HIV virus needs to insert its genetic material into human cells. It is always used as part of a combination antiretroviral therapy regimen.

Yes, Elvitegravir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL204656. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5277135. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.